Real-World Evidence (RWE)

Data collected from everyday patient care (like electronic health records) used to prove an AI tool actually works and is safe in the real world, not just in a highly controlled, artificial lab experiment.

The Simple Version

Data collected from everyday patient care (like electronic health records) used to prove an AI tool actually works and is safe in the real world, not just in a highly controlled, artificial lab experiment.

Detailed Explanation

In healthcare AI, RWE is increasingly required by regulators (e.g., the FDA, EMA) for the post-market surveillance of AI/ML-based Software as a Medical Device (SaMD). It is used to monitor model drift, validate ongoing clinical effectiveness, and ensure long-term patient safety across diverse, uncontrolled patient populations outside of rigid, traditional clinical trials.

Key Characteristics

• Derived from Routine Care: Data is generated during normal clinical workflows, not controlled experimental conditions.
• Post-Market Focus: Critical for monitoring AI performance after it has been deployed to the general public.
• Diversity: Captures a broader, more representative slice of the population than traditional clinical trials.

Common Misconceptions

• Myth: RWE is just messy, unreliable data compared to clinical trials.
• Myth: RWE can replace clinical trials entirely.

Related Terms

• clinical validation
• fda approval samd
• ehr integration
• model monitoring

Sources & Further Reading

• AI Dictionary of Terms by Alex Nubla — MIT License
• Original AI Dictionary entry
• FDA: Framework for Real-World Evidence Program
• EMA: Guideline on the use of Real-World Data and Real-World Evidence

Real-World Evidence (RWE): Direct Definition

Data collected from everyday patient care (like electronic health records) used to prove an AI tool actually works and is safe in the real world, not just in a highly controlled, artificial lab experiment.

Technical Definition

In healthcare AI, RWE is increasingly required by regulators (e.g., the FDA, EMA) for the post-market surveillance of AI/ML-based Software as a Medical Device (SaMD). It is used to monitor model drift, validate ongoing clinical effectiveness, and ensure long-term patient safety across diverse, uncontrolled patient populations outside of rigid, traditional clinical trials.

Why It Matters